T1D Exchange

T1D Exchange
Name	T1D Exchange
Formation	2010
Type	Nonprofit research consortium
Headquarters	Boston, Massachusetts
Region served	United States
Focus	Type 1 diabetes research, clinical registries

T1D Exchange is a United States–based nonprofit research consortium focused on improving outcomes for people with type 1 diabetes through observational research, registries, and quality improvement initiatives. It connects clinical centers, academic institutions, biotechnology companies, patient advocacy organizations, and regulatory agencies to generate real‑world evidence and accelerate therapeutic development. The organization engages clinicians, people with diabetes, and industry partners to collect longitudinal data, facilitate pragmatic trials, and inform guidelines.

Overview

T1D Exchange operates a multicenter network that links pediatric and adult centers such as Boston Children's Hospital, Massachusetts General Hospital, Johns Hopkins Hospital, Mayo Clinic, and UCLA Medical Center with research infrastructure used by investigators affiliated with Harvard Medical School, Stanford University School of Medicine, Yale School of Medicine, University of Pennsylvania, and University of Michigan. The consortium's registry and platform enable studies that intersect with regulators and funders including the U.S. Food and Drug Administration, National Institutes of Health, Patient-Centered Outcomes Research Institute, and private sponsors like JDRF and pharmaceutical firms such as Eli Lilly and Company, Novo Nordisk, and Sanofi. Programmatic activities bring together clinicians from networks like American Diabetes Association, investigators who publish in journals such as The New England Journal of Medicine, The Lancet, and Diabetes Care, and patient advocates associated with groups like American Association of Clinical Endocrinologists.

History and Formation

Founded in 2010, T1D Exchange emerged from collaborations among academic leaders at institutions including Massachusetts General Hospital, Joslin Diabetes Center, Baylor College of Medicine, University of Colorado Anschutz Medical Campus, and Seattle Children's Hospital. Early governance included physician‑investigators with ties to centers such as Cleveland Clinic, Children's Hospital of Philadelphia, and Mount Sinai Health System, and was informed by stakeholders from advocacy entities like JDRF and clinical trial units connected to Duke University School of Medicine. The consortium built its initial funding and operational model through relationships with agencies such as the National Institute of Diabetes and Digestive and Kidney Diseases and philanthropic contributors reminiscent of donors to Howard Hughes Medical Institute–supported programs, while aligning with trial design principles familiar to teams at Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute.

Research Programs and Registries

The core asset is a longitudinal registry that aggregates clinical, device, and patient‑reported data from participating centers including Cincinnati Children's Hospital Medical Center, Children's National Hospital, Rady Children's Hospital, St. Jude Children's Research Hospital, and Providence St. Joseph Health sites. The registry supports observational cohorts, pragmatic trials, and device surveillance that intersect with technologies from makers like Medtronic, Dexcom, and Insulet Corporation. Investigators leverage the platform for comparative effectiveness studies, natural history research, and endpoints used by consortia such as TrialNet and initiatives at Imperial College London and University of Oxford. Data elements are harmonized to standards employed in repositories like Observational Health Data Sciences and Informatics and clinical terminologies referenced by World Health Organization frameworks.

Data Governance and Ethics

Data governance models draw on practices used by entities such as Partners HealthCare, Veterans Health Administration, All of Us Research Program, and consortia that negotiate data use agreements with academia and industry, ensuring institutional review board oversight from centers like University of California, San Francisco and Columbia University Irving Medical Center. Ethical oversight involves patient representation similar to advisory roles in Patient-Centered Outcomes Research Institute projects and privacy safeguards informed by laws and guidelines like those administered by the U.S. Department of Health and Human Services and practices seen in European networks such as European Medicines Agency. The governance framework balances data sharing for research with protections analogous to policies at National Institutes of Health data repositories.

Collaborations and Partnerships

T1D Exchange partners with academic health systems, device manufacturers, payers, and advocacy groups to enable studies and quality improvement collaboratives. Notable collaborative linkages include clinical trial partnerships reminiscent of work with Eli Lilly and Company, device evaluations involving Dexcom and Medtronic, and policy dialogues engaging stakeholders like Centers for Medicare & Medicaid Services and Children's Hospital Association. Research collaborations extend internationally, intersecting with programs at Karolinska Institutet, University of Toronto, Monash University, and global organizations such as World Health Organization and International Diabetes Federation.

Impact and Outcomes

Findings from registry analyses and pragmatic studies have informed clinical practice elements found in guidelines from the American Diabetes Association and consensus statements adopted by societies like American Association of Clinical Endocrinologists and have been cited in peer‑reviewed publications similar to articles in The New England Journal of Medicine and Diabetes Care. The consortium's data have contributed to evaluations of continuous glucose monitoring, insulin pump therapy, hybrid closed‑loop systems, and disparities research paralleling work at Centers for Disease Control and Prevention and Kaiser Permanente. Quality improvement initiatives have produced center‑level benchmarking used by networks such as Pediatric Research in Inpatient Settings and have supported regulatory submissions to the U.S. Food and Drug Administration.

Category:Diabetes organizations